Navigation Links
Vectibix® (Panitumumab) Granted Approval for Expanded Indications in the European Union
Date:11/15/2011

ement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. FDA, European Medicines Agency (EMA) or similar regulatory bodies for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. Only the FDA, EMA or similar regulatory bodies can determine whether the products are safe and effective for these uses. Healthcare professionals should refer to and rely upon the approved labeling for the products, and not the information discussed in this news release.

(1) Jemal. Global Cancer Statistics. CA CANCER J CLIN 2011;61:69–90

(2) Douillard, JE et al. Randomized, Phase 3 Study (PRIME) of Panitumumab with FOLFOX4 versus FOLFOX4 Alone as First-Line Treatment in Patients With Previ
'/>"/>

SOURCE Amgen Europe GmbH
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Amgen to Appeal CHMP Opinion on Vectibix® (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe
2. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
3. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
4. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
5. Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery
6. Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA
7. Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
8. Emphasys Medical Granted Expedited Review From FDA for Zephyr(R) Endobronchial Valve
9. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
10. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
11. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 22, 2015  In a sweeping analysis assessing the ... T1D Exchange researchers conclude that there remains considerable ... across all age groups, but especially for adolescents and ... of diabetes treatment, underscoring the need to address barriers ... can help type 1 patients achieve optimal metabolic control. ...
(Date:5/21/2015)... , May 21, 2015  When ... along the side of his neck, he ... took a couple weeks off from weight ... go away.                               A ... 26, was referred to Michel Kliot, ...
(Date:5/21/2015)... , May 21, 2015  Cardica, Inc. (Nasdaq: CRDC ... Greg Watson , the company,s vice president of operations, ... company,s common stock, at a per share exercise price of ... stock option was granted pursuant to Cardica, Inc.,s Inducement Plan, ... May 2015 under Rule 5653(c)(4) of the Nasdaq Global Market ...
Breaking Medicine Technology:Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 2Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 3Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 5Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 3Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 4Cardica Announces New Employment Inducement Grant 2
... Dec. 29, 2010 Reportlinker.com announces that a new ... Mammography World Markets ... poised for a major new phase of growth fueled ... the computer and digital areas and the higher interest ...
... (Nasdaq: OMER ), a biopharmaceutical company ... on inflammation and disorders of the central nervous ... clinical trial of OMS201, the Company,s urological PharmacoSurgery™ ... an anti-inflammatory agent and a smooth muscle relaxant, ...
Cached Medicine Technology:Reportlinker Adds Mammography World Markets 2Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy 2Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy 3
(Date:5/24/2015)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) May 24, ... sees many patients for concerns about hair loss. ... loss, it is clear that there are environmental factors ... of hormone that can contribute. Since they offer a ... aspects of the peri and post-menopausal woman, they can ...
(Date:5/24/2015)... EnviroLeather™ by LDI, a leader in ... classic, rugged leather grain with enhanced stain resistance ... ink, to be easily removed. The collection is ... healthcare, hospitality and education environments. , InkGard Plus ... developing products that are more sustainable, less toxic ...
(Date:5/24/2015)... 2015 Medicx Media Solutions ... executive Jay Krihak as its head of programmatic ... up its expertise and leadership position in the ... Health sectors. , Krihak is an experienced, award-winning ... Krihak led sales planning teams for mobile platform ...
(Date:5/23/2015)... On May 13, Nithyananda Yoga Foundation organized a ... learned through meditation and initiation at Special Holistic School ... Yogamaatha, a nine-year-old girl from North Carolina, stunned an ... the 2015 Business Advocacy Summit at Capitol Hill in ... In a demonstration that lasted three hours, Yogamaatha was ...
(Date:5/23/2015)... May 23, 2015 On May 16, the ... The event was a 5k mud obstacle run that raised ... 2 million people worldwide, and the reason we participated was ... Chad Davis, owner of Farrell’s eXtreme Bodyshaping. “One-hundred percent of ... Society.” , The event was not only attended by eXtreme ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Now Treats Menopausal Hair Loss 2Health News:EnviroLeather By LDI Launches "InkGard Plus" - Stain Resistant Faux Leather 2Health News:Medicx Media Solutions Expands Executive Team 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3Health News:Farrell’s eXtreme Bodyshaping Team Runs through the Muck for MS 2
... part of health, and assessment of sleep habits should be ... in the September 18 issue of Archives of Internal Medicine ... devoted to studies of sleep and health. ,"The ... as an indicator of health and quality of life and ...
... the times, warns the U.S. Food and Drug Administration// (FDA). ... Georgia that was believed to occur due to the consumption ... three cases were reported on September 15. Other consumers of ... not have any complaints as they had properly refrigerated it., ...
... official government assessment of a ?1 million public consultation project ... fake//. ,Your Health, Your Care, Your Say was ... a say in a White Paper on health published this ... complained that they had no influence on the final policies.14% ...
... A recent report by the Ministry in Jamaica has revealed ... a paper that has now come before the House of// ... virus live healthy lives for several years without developing the ... the performance of the National HIV/STI Control Programme, and states ...
... lot more funds are needed from the rich countries to ... five by two-thirds.// ,Five times more money is ... one of the series of papers published online by the ... the journal, UNICEF and the Norwegian government. , ...
... to improve HIV/AIDS treatment and evolve better prevention strategies, ... into an agreement this month, to formally seal their ... free nation. It is well known that, The Clinton ... to eliminate AIDS from the planet. ...
Cached Medicine News:Health News:Incorporate Sleep Evaluation into Routine Medical Care 2Health News:A million Pound Public consultation - declared a sham!! 2Health News:Child death reduction needs five times more funds 2
... For fast, single-solution staining, Hema-Quik ... Dip slides into stain solution ... transfer to deionized water for ... a second time by dipping ...
This stain is the McNeal formula and can be substituted for Wright Stain solution....
This Wright-Giemsa is a dual-use stain for peripheral blood and bone marrow smears. It produces somewhat darker results when compared with Giemsa, particularly in the blue to magenta shades....
Albumin (BCG). Storage temp: 15 -30 C. Linearity: 0.5 - 6.0 g/dl. Expected values: 3.5 - 5.5 g/dl. Available with calibrator. Performs 500 number of tests....
Medicine Products: